David P Ryan MD

Oncology•Boston, MA

Gastrointestinal Cancer, Hematologic Oncology

Chief, Hematology-Oncology, Clinical Director, MGH Cancer Center

Join to View Full Profile

55 Fruit StYaw 7eBoston, MA 02114
Phone+1 617-724-0245
Fax+1 617-724-3166

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1992

Certifications & Licensure

MA State Medical License 1996 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013

Clinical Trials

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Start of enrollment: 2004 Jul 01
Unknown status
Phase 3
Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Start of enrollment: 2008 May 01
Terminated
Phase 2
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma Start of enrollment: 2008 Apr 01
Terminated
Phase 1, Phase 2
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2012 Jul 01
Completed
Phase 2
Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
Completed
Phase 2
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Start of enrollment: 2014 Sep 01
Terminated
Phase 2
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Start of enrollment: 2016 Jun 14
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of 2 Prospective Trials.
Grace Lee, Bailey Nelson, Julie Koenig, John P Plastaras, James M Metz
International Journal of Radiation Oncology, Biology, Physics. 2025-01-10
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.
Grace Lee, Daniel W Kim, Alicia C Smart, Nora K Horick, Christine E Eyler
American Journal of Clinical Oncology. 2024-08-01
1 citations
Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma.
Guoliang Qiao, Zhi Ven Fong, Louisa Bolm, Carlos Fernandez Del-Castillo, Cristina R Ferrone
Annals of Surgery. 2024-07-01

Lectures

Optimizing Locoregional Management in the Context of Multidisciplinary Care
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

Other

Clinical features, staging, and treatment of anal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/clinical-features-staging-and-treatment-of-anal-cancer
UpToDate, Wolters Kluwer Health - 2013-03-26
Ampullary carcinoma: Treatment and prognosis
Ryan DP, Castillo CF, Mamon H
http://www.uptodate.com/contents/ampullary-carcinoma-treatment-and-prognosis
UpToDate, Wolters Kluwer Health - 2012-07-19
Classification and epidemiology of anal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/classification-and-epidemiology-of-anal-cancer
UpToDate, Wolters Kluwer Health - 2012-12-20
Adjuvant therapy for resected rectal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/adjuvant-therapy-for-resected-rectal-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09
Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/neoadjuvant-chemoradiotherapy-and-radiotherapy-for-rectal-cancer
UpToDate, Wolters Kluwer Health - 2013-03-18
Treatment of locally advanced unresectable or recurrent rectal cancer
Ryan DP, Willett CG, Rodriguez-Bigas MA
http://www.uptodate.com/contents/treatment-of-locally-advanced-unresectable-or-recurrent-rectal-canc
UpToDate, Wolters Kluwer Health - 2013-03-28
Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer
Ryan DP, Mamon H
http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-therapy-for-exocrine-pancreatic-cancer
UpToDate, Wolters Kluwer Health - 2013-02-19
Chemotherapy for advanced exocrine pancreatic cancer
Ryan DP
http://www.uptodate.com/contents/chemotherapy-for-advanced-exocrine-pancreatic-cancer
UpToDate, Wolters Kluwer Health - 2013-04-01
Management of locally advanced and borderline resectable exocrine pancreatic cancer
Ryan DP, Mamon H
http://www.uptodate.com/contents/management-of-locally-advanced-and-borderline-resectable-exocrine-p
UpToDate, Wolters Kluwer Health - 2013-04-10
Join now to see all

Press Mentions

New Dana-Farber Cancer Hospital Wins Key State Approval, Despite Mass General Brigham ConcernsMarch 20th, 2025
Community Oncology Policy Problems Solved Soon? 2025 a “Make-or-Break” Year for ReformJanuary 13th, 2025
After Dana-Farber Split, Mass General Brigham Cuts New Cancer PathDecember 3rd, 2024
Join now to see all